ストックスクリーナーアプリを入手
2.36
1.67%
-0.04
プレマーケット:
2.38
0.02
+0.85%
前日終値:
$2.40
開ける：
$2.39
24時間の取引高:
262.01K
Relative Volume:
1.25
時価総額：
$78.04M
収益：
-
当期純損益:
$-32.94M
株価収益率:
-2.1261
EPS:
-1.11
ネットキャッシュフロー:
$-24.95M
1週間 パフォーマンス:
+18.59%
1か月 パフォーマンス:
-17.48%
6か月 パフォーマンス:
-49.89%
1年 パフォーマンス:
-48.42%
1日の値動き範囲:
$2.36
$2.48
1週間の範囲:
$1.96
$2.63
52週間の値動き範囲:
$1.84
$5.59
Achieve Life Sciences Inc Stock (ACHV) Company Profile
名前
Achieve Life Sciences Inc
セクター
電話
425-686-1500
住所
22722 29TH DR. SE, SEATTLE, BC
ACHV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
2.36 | 78.04M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
| 2024-09-27 | 開始されました | Raymond James | Strong Buy |
| 2023-05-10 | 繰り返されました | Maxim Group | Buy |
| 2021-06-23 | 開始されました | Oppenheimer | Outperform |
Achieve Life Sciences Inc (ACHV) 最新ニュース
Press Release Distribution & PR Platform - ACCESS Newswire
Here are Rogue Funds Updates on Achieve Life Sciences (ACHV) - MSN
LPL Financial LLC Has $693,000 Stock Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Achieve Life Sciences announces publication of results from Phase 3 ORCA-3 trial - Yahoo Finance
Cytisinicline shows promise for smoking cessation By Investing.com - Investing.com South Africa
Achieve Life Sciences Expects to File New Drug Application in US for Smoking Cessation Medication - marketscreener.com
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine | ACHV Stock News - GuruFocus
Achieve Life Sciences (ACHV) Confirms Cytisinicline Efficacy in Phase 3 ORCA-3 Trial | ACHV Stock News - GuruFocus
Cytisinicline’s FDA Path Ignites ACHV Stock: Could This Biotech Gem Soar on Smoking and Vaping Cessation Breakthroughs? - Own Snap
Achieve Life Sciences Announces Cytisinicline Phase 3 - GlobeNewswire
Breakthrough Smoking Cessation Drug Outperforms Existing Treatments in Major Phase 3 Trial, JAMA Reports - Stock Titan
157,519 Shares in Achieve Life Sciences, Inc. (NASDAQ:ACHV) Purchased by Raymond James Financial Inc. - MarketBeat
Raymond James Financial Inc. Invests $554,000 in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
ACHV Stock Touches 52-Week Low at $2.5 Amid Market Challenges - Investing.com UK
ACHIEVE LIFE SCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Contrasting Achieve Life Sciences (NASDAQ:ACHV) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Achieve Life Sciences (ACHV) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Insider Buying: Mark Oki Acquires Shares of Achieve Life Sciences Inc (ACHV) - GuruFocus
Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory - MSN
Achieve Life Sciences CEO Richard Stewart purchases $28,598 in stock - Investing.com India
Achieve Life Sciences CFO Mark Oki buys $28,887 in stock - Investing.com India
Achieve Life Sciences (ACHV) Expected to Announce Quarterly Earnings on Thursday - Defense World
Achieve Life Sciences Executives Acquire Shares - TradingView
Achieve Life Sciences CFO Mark Oki buys $28,887 in stock By Investing.com - Investing.com UK
Achieve Life Sciences CEO Richard Stewart purchases $28,598 in stock By Investing.com - Investing.com UK
Achieve Life Sciences: Promising Clinical Progress and Strategic Leadership Enhancements Justify Buy Rating - TipRanks
ACHV stock touches 52-week low at $2.81 amid market challenges - Investing.com India
Achieve Life Sciences (NASDAQ:ACHV) Announces Earnings Results - MarketBeat
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2024 Earnings Call Transcript - Insider Monkey
ACHV: 2Q:25 NDA Submission - Yahoo Finance
Achieve Life Sciences Inc (ACHV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo
Achieve Life Sciences Reports 2024 Financial Results - TipRanks
Achieve Life Sciences misses Q4 earnings, shares fall By Investing.com - Investing.com South Africa
Achieve Life Sciences misses Q4 earnings, shares fall - Investing.com
Earnings call transcript: Achieve Life Sciences Q4 2024 sees slight EPS miss By Investing.com - Investing.com South Africa
Earnings call transcript: Achieve Life Sciences Q4 2024 sees slight EPS miss - Investing.com
Achieve Life Sciences Q4 Loss Widens - Nasdaq
Achieve Life Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program - The Manila Times
ACHIEVE LIFE SCIENCES Earnings Results: $ACHV Reports Quarterly Earnings - Nasdaq
ACHIEVE LIFE SCIENCES, INC. SEC 10-K Report - TradingView
Achieve Life Sciences Announces Planned NDA Submission for Cytisinicline Targeting End of Q2 2025 - Nasdaq
Achieve Life Sciences Reports Financial Results for Fourth - GlobeNewswire
Achieve Life Sciences Hits Major FDA Milestone as Q4 Results Show $34.4M Cash Position - StockTitan
Earnings Scheduled For March 11, 2025 - Benzinga
SBI Securities Co. Ltd. Purchases New Shares in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Achieve Life Sciences (ACHV) Projected to Post Earnings on Tuesday - Defense World
Can This Smoking Cessation Drug Developer Disrupt a $20B Market? Key Presentation Coming - StockTitan
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference - The Manila Times
Achieve Life Sciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025 - The Manila Times
Achieve Life Sciences Inc (ACHV) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
36.06%
大文字化:
|
ボリューム (24 時間):